Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gastrointestinal carcinoid tumor
Trial Type:  Treatment
Results 1-13 of 13 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Pazopanib Hydrochloride in Treating Patients with Progressive Carcinoid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A021202, NCI-2013-00831, ALLIANCE A021202, CALGB-A021202, NCT01841736
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OX4219s, NCI-2015-00120, NCT02279602
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
Ribociclib in Treating Patients with Advanced Neuroendocrine Tumors of Foregut Origin
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0371, NCI-2015-01017, NCT02420691
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNX5422-CLN-009, NCI-2014-02577, NCT02063958
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BrUOG 265, NCI-2015-00258, 9882, NCT02381561
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, NCT02631733
68Ga-DOTA-JR11and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737
Start Over